Enzalutamide in Japanese patients with chemotherapy‐naïve, metastatic castration‐resistant prostate cancer: A post‐hoc analysis of the placebo‐controlled PREVAIL trial

To evaluate the treatment effects, safety and pharmacokinetics of enzalutamide in Japanese patients.

• Publication year

  2016

• Venue

  International journal of urology

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/iju.13072PMID 27018069
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer

  2015cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)

  2014cited by this paper
• GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer

  2013cited by this paper
• GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]

  2013cited by this paper
• Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer.

  2013cited by this paper
• Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.

  2013cited by this paper
• An overview of prostate diseases and their characteristics specific to Asian men.

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Prostate cancer: an emerging threat to the health of aging men in Asia.

  2011cited by this paper
• Drug resistance in metastatic castration-resistant prostate cancer

  2011cited by this paper
• Prostate Cancer Working Group report.

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

  2008cited by this paper
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

  2008cited by this paper
• Prostate-specific antigen levels among Chinese, Malays and Indians in Singapore from a community-based study.

  2007cited by this paper
• Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer

  2006cited by this paper
• Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

  2005cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• The development of androgen-independent prostate cancer

  2001cited by this paper
• Androgen receptor signaling in androgen-refractory prostate cancer.

  2001cited by this paper
• Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study.

  1996cited by this paper
• Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men.

  1995cited by this paper
• Pain assessment: global use of the Brief Pain Inventory.

  1994cited by this paper
• Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

  1993cited by this paper
• Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

  1989cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper

• Should Upfront Therapy With Androgen Receptor Signaling Inhibitors Be Used in All Japanese Patients With Metastatic Castration-sensitive Prostate Cancer?

  2025cites this paper
• Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial

  2025cites this paper
• Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study

  2024cites this paper
• エンザルタミドとカルシウム拮抗薬の薬物相互作用が血圧変動に及ぼす影響

  2023cites this paper
• Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice

  2022cites this paper
• Androgen receptor axis-targeted agents are not superior to conventional hormonal therapy for treatment of metastatic prostate cancer

  2022cites this paper
• High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients

  2021cites this paper
• Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer

  2021cites this paper
• Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study

  2021cites this paper
• Comparison of efficacy outcomes of anticancer drugs between Japanese patients and the overall population

  2020cites this paper
• Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic Prostate Cancer: Meta-Analysis of Randomized Controlled Trials.

  2020cites this paper
• Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan

  2020cites this paper
• Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer

  2020cites this paper
• Reduction of Initial Dose of Enzalutamide does not Decrease the Incidence and Severity of Adverse Events in Castration-Resistant Prostate Cancer

  2020cites this paper
• Development of a HPLC-UV Method for the Quantitative Determination of Enzalutamide and its Active Metabolites in Human Plasma

  2020cites this paper
• Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

  2019cites this paper
• Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study

  2019cites this paper
• Enzalutamide: A Review in Castration-Resistant Prostate Cancer

  2018cites this paper
• Survival Outcomes, Prostate‐specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration‐resistant Prostate Cancer: A Real‐World Experience in Hong Kong

  2018cites this paper
• Enzalutamide Therapy for mCRPC in Japanese Men

  2018cites this paper
• Therapies for castration‐resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines

  2017cites this paper
• Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.

  2017cites this paper
• Influences of the Results from STRIVE Trial on the Combination Androgen Depletion Therapy for Advanced Prostate Cancer

  2016cites this paper
• Post hoc analysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer—updated results

  2016cites this paper
• Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment

  2016cites this paper